BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37356936)

  • 21. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
    Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Wang J; Zhou M; Xu JY; Yang YG; Zhang QG; Zhou RF; Chen B; Ouyang J; Li C
    Histol Histopathol; 2016 Mar; 31(3):285-92. PubMed ID: 26424560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Cancer Sci; 2012 Oct; 103(10):1898-904. PubMed ID: 22783941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.
    Sang W; Zhou H; Qin Y; Shen Z; Yan D; Sun C; Song X; Ma Y; Tu D; Bian Z; Nie S; Jin Y; Xu L; Li Z; Xu K
    Int J Hematol; 2021 Aug; 114(2):189-198. PubMed ID: 33893987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of
    Qin Y; Chen H; Liu P; Zhang C; Yang J; Gui L; He X; Zhou L; Zhou S; Jiang S; Jiang H; Shi Y
    Cancer Biol Med; 2021 Nov; 19(6):893-909. PubMed ID: 34806851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.
    Yin T; Qi L; Zhou Y; Kong F; Wang S; Yu M; Li F
    J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.
    Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
    Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.
    Lossos IS; Jones CD; Warnke R; Natkunam Y; Kaizer H; Zehnder JL; Tibshirani R; Levy R
    Blood; 2001 Aug; 98(4):945-51. PubMed ID: 11493437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
    Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
    Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
    Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
    Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nomogram based on the systemic immune-inflammation index for predicting the prognosis of diffuse large B-cell lymphoma.
    Wu J; Zhu H; Zhang Q; Sun Y; He X; Liao J; Liu Y; Huang L
    Asia Pac J Clin Oncol; 2023 Apr; 19(2):e138-e148. PubMed ID: 35754170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The prognostic impact of diabetic mellitus and hyperglycemia during DLBCL treatment on patients with diffuse large B-cell lymphoma].
    Hu Y; Xu YJ; Li MZ; Lan YX; Mao L; Ning QY; Xu W; Yang HL; Zhang YZ
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):151-157. PubMed ID: 33858047
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients.
    Luo H; Yi P; Wang W; Li K; Meng L; Li J; Zeng W; Tang M
    Med Sci Monit; 2019 Nov; 25():8671-8682. PubMed ID: 31734687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of nomogram prognostic model for predicting OS in patients with diffuse large B-cell lymphoma: a cohort study in China.
    Li X; Xu Q; Gao C; Yang Z; Li J; Sun A; Wang Y; Lei H
    Ann Hematol; 2023 Dec; 102(12):3465-3475. PubMed ID: 37615680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What factors are associated with the prognosis of primary testicular diffuse large B-cell lymphoma? A study based on the SEER database.
    Yang S; Chang W; Zhang B; Shang P
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10269-10278. PubMed ID: 37270733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nomograms based on SUVmax of
    Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
    Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.